GKOS Stock Gains Following Positive Study Data on iDose Platform

iDose TR Clinical Data and Market Impact - iDose TR demonstrated sustained efficacy in a 36-month follow-up analysis, with 70% of patients remaining well-controlled on the same or fewer IOP-lowering medications compared to 58% in the control group [4] - The implant achieved a mean IOP reduction of 11.3 mmHg (44%) at six months post-operation in a Phase 4 study involving 60 open-angle glaucoma patients [6] - iDose TR received FDA approval in December 2023 for reducing intraocular pressure in patients with ocular hypertension or open-angle glaucoma [2] iDose TREX Development - Glaukos initiated Phase 2b/3 clinical trials for iDose TREX, the next-generation sustained-release platform with nearly double the drug capacity of iDose TR [8] - Early-stage clinical updates suggest iDose TREX could extend therapeutic efficacy duration and enhance patient outcomes [8] Financial Performance and Market Position - GKOS shares gained 17.7% in the past six months against the industry's 0.6% decline [3] - The company's glaucoma franchise witnessed revenue growth in Q3, driven by iStent portfolio and growing contributions from iDose TR [11] - Glaukos successfully executed detailed launch plans for iDose TR in Q3, with the unique permanent J-code becoming effective on July 1 [11] Competitive Landscape - The positive clinical data on iDose TR and advancement of iDose TREX provide Glaukos with a significant competitive advantage in the ophthalmic market [9] - iDose positions Glaukos as a leader in procedural pharmaceutical solutions by addressing critical challenges in glaucoma treatment [9]